Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xgeva (Denosumab) for the Prevention of Metastatic Bone Cancer

Drug (Brand/Generic)

Xgeva / Denomusab

Company/Licensee

Amgen

Product Description

A fully human monoclonal antibody with ability to inhibit the RANK Ligand

Current Indication

Prevention of Bone Metastasis and SRE's

Market Sector

Oncology

Development Status

Approved in US, UK and Canada
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top